All News
Long-Term Survival of Idiopathic Inflammatory Myopathies
A single center cohort study analyzed the outcome and survival of IIM patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
https://t.co/oEuTNiUANc https://t.co/1lXiStqoEz
Links:
Dr. John Cush RheumNow ( View Tweet)
Should be revisit role of #MTX in OA?
Possibly some benefit in metabolically active #osteoarthritis
#RNL2023 #methotrexate https://t.co/DIxIYQNulv
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
MTX as a treatment of OA, by Dr.Conaghan #RNL2023 @RheumNow
Systemic inflammation might also be a part of OA?! https://t.co/grxMKtRLhj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
⚠️Only 12-43% of #PsA patients achieved remission or very low disease activity
From systematic review in RWE presented by @DrLauraCoates
#RNL2023
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
@Rheumnow https://t.co/hA7JDR7Zyh
Eric Dein ericdeinmd ( View Tweet)
I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL
Dr. Rachel Tate uptoTate ( View Tweet)
Treat to target in PSA: What's difference in our outcome scores?
DAPSA: includes CRP
MDA: includes enthesitis, skin, function
Both metrics include Tender/Swollen jt counts, and pt pain/global
Presented by @DrLauraCoates at #RNL2023
@RheumNow https://t.co/7i5m70HGiz
Eric Dein ericdeinmd ( View Tweet)
Dr. Laura Coates presents - Is remission in PsA attainable?
systematic review: 12-43% achieved very low disease activity or remission
#RNL2023 @RheumNow https://t.co/flfpzc7B4p
Robert B Chao, MD doctorRBC ( View Tweet)
Triamcinolone joint injection, Dr.Conaghan #RNL2023 @RheumNow
Extended half life steroids injections are better?!:
1- better for sugar control.
2-longer effect. https://t.co/4T8frPJOXG
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2023 @RheumNow
@DrLauraCoates: patients & physicians do not agree on what is remission in PsA
Patients global scores: largely driven by pain and fatigue, not on joint counts
Remission in PsA allows for disease control on Rx- not just drug-free remission, often not sustained https://t.co/Hr2uuWDAfr
Eric Dein ericdeinmd ( View Tweet)
Higher Rehospitalization Rates in Younger SLE Patients
A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
https://t.co/17Lbcw8TdC https://t.co/L6CwRCd1aS
Links:
Dr. John Cush RheumNow ( View Tweet)
Can we prevent RA, Kevin Deane #RNL2023 @RheumNow. https://t.co/EtUEs3MyCN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Upto 30% risk of #RA within 5 yrs if anti-CCP positive
#RNL23 https://t.co/E5wun837ud
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Conaghan: "Most promising study in OA" at #RNL2023
NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated?
Can there be sustained response.
Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪
@RheumNow https://t.co/eBMEPBG9wn
Eric Dein ericdeinmd ( View Tweet)
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/2Y5am2YEsQ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Conaghan shares unpublished data from PROMOTE study at #RNL2023
Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active.
Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA
@RheumNow https://t.co/Ieagp8mq31
Eric Dein ericdeinmd ( View Tweet)
30% rule!
Risk of RA development in Pre clinical RA patient in the next 3 to 5 years .
Kevin Deane #RNL2023 @RheumNow https://t.co/J6Polz70im
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr Philip Conaghan at #RNL2023
X-rays are misleading in OA
OA is a CLINICAL disease
Radiographs do not help in diagnosis or monitoring
@RheumNow https://t.co/ZrAfPN02qi
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/zJRRisGW9i
Eric Dein ericdeinmd ( View Tweet)
@RheumNow Live #RNL2023
Stanley Cohen, MD:
Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16
ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG
Eric Dein ericdeinmd ( View Tweet)